T2000 in Essential Tremor - Open Label Continuation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00655278
Recruitment Status : Terminated
First Posted : April 9, 2008
Last Update Posted : December 23, 2013
Information provided by (Responsible Party):
Taro Pharmaceuticals USA

Brief Summary:
This study will evaluate the safety and efficacy of T2000 when used to treat patients with moderate to severe essential tremor over an 18 month period.

Condition or disease Intervention/treatment Phase
Essential Tremor Drug: T2000 Phase 2

Detailed Description:

Essential tremor (ET) is a common form of involuntary shaking not related to Parkinson's disease. The medications that are currently used to treat ET work in a small proportion of patients and provide only partial improvement in symptoms. Use of these current medications is also limited by side-effects in many patients.

T2000 is a medication currently under development for the treatment of essential tremor. Although T2000 is a new medication, it belongs to a class of medications that has been used for many years for the treatment of a variety of medical conditions. In previous studies, T2000 appeared to be effective in controlling symptoms of ET and some patients with severe ET had major improvements in tremor. In some patients T2000 was well tolerated for periods up to 5 months and the minimal side-effects seen were those that would be expected for medications in this class.

The current study will evaluate the safety and efficacy of T2000 in patients with moderate to severe essential tremor. Patients will receive doses of T2000 beginning at 600 mg a day, followed by 800 mg a day and up to 1000 mg a day. The total duration of treatment will be 18 months. Patient's tremor and neurological examination will be monitored throughout the study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric Acid) in Patients With Essential Tremor: An Open-Label Dose Continuation Study
Study Start Date : August 2007
Actual Primary Completion Date : November 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tremor
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
T2000 at 600-1000 mg daily
Drug: T2000
T2000 at previous most effective, well-tolerated dose (600-1000mg daily)

Primary Outcome Measures :
  1. Effect of treatment on tremor will be measured by a tremor scale as well as by assessment of functional activity with specific tasks. [ Time Frame: Up to 18 months ]

Secondary Outcome Measures :
  1. Safety parameters including neurological examination, blood tests and EKG will be monitored throughout the treatment period and during withdrawal of the medication. [ Time Frame: Up to 18 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients will be enrolled following completion of a dose escalation trial (such as T2000-0533)

  • Confirmed essential tremor by NIH criteria
  • Significant functional activity limitation due to ET
  • Patients who have failed, are inadequately treated or cannot tolerate alternative treatments for ET as well as treatment naïve patients who have considered but declined alternative treatment

Exclusion Criteria:

  • Patients adequately controlled without side effects on a current ET treatment
  • Pregnant patients or patients who may become pregnant during the study
  • Patients with other medical conditions that may cause tremor, such as Parkinson's disease or active hyperthyroidism
  • Patients taking medications that might produce tremor or interfere with the evaluation of tremor such as CNS-stimulants or beta-blockers
  • Patients who must take medications that alter liver metabolism as well as patients with liver disease or coagulation disorders
  • Patients with seizure disorders
  • Patients with a history of allergy or hypersensitivity reaction to barbiturates or other related medications, such as phenobarbital or phenytoin
  • Patient with significant general medical or clinical laboratory abnormalities

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00655278

Canada, Ontario
Investigator Site
London, Ontario, Canada
Investigator Site
Ottawa, Ontario, Canada
Investigator Site
Toronto, Ontario, Canada
Sponsors and Collaborators
Taro Pharmaceuticals USA

Responsible Party: Taro Pharmaceuticals USA Identifier: NCT00655278     History of Changes
Other Study ID Numbers: T2000-0639
First Posted: April 9, 2008    Key Record Dates
Last Update Posted: December 23, 2013
Last Verified: November 2013

Keywords provided by Taro Pharmaceuticals USA:
Movement Disorder

Additional relevant MeSH terms:
Essential Tremor
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Movement Disorders
Central Nervous System Diseases